Vo
lu
m
e
5,
Ju
ne
,2
02
5
,
M
ED
IC
AL
SC
IE
N
CE
S.
IM
PA
CT
FA
CT
OR
:7
,8
9
OCULAR INVOLVEMENT IN RHEUMATOID ARTHRITIS
Kuzibaeva Izzakhon Begali kizi
Fergana Public Health Medical Institute, Department of Internal Diseases
Abstract:
Rheumatoid arthritis (RA) is a chronic systemic autoimmune disease primarily
affecting joints but frequently involving extra-articular organs, including the eyes. Ocular
manifestations in RA patients range from mild keratoconjunctivitis sicca to severe sight-
threatening conditions such as uveitis, scleritis, and optic neuritis. Early diagnosis and
multidisciplinary management are crucial to prevent irreversible vision loss and improve
patients’ quality of life. This review summarizes the pathogenesis, clinical presentations,
diagnostic methods, and current treatment approaches for ocular involvement in RA.
Emphasis is placed on the importance of timely ophthalmologic evaluation and integrated
therapeutic strategies to optimize patient outcomes.
Keywords:
Rheumatoid arthritis, ocular involvement, keratoconjunctivitis sicca, uveitis,
scleritis, diagnosis, treatment, autoimmune disease, immunosuppressive therapy
Introduction
Rheumatoid arthritis (RA) is a chronic, systemic autoimmune disease characterized
primarily by persistent inflammation of the synovial joints. It affects approximately 0.5–1%
of the global population and is associated with progressive joint destruction, functional
disability, and reduced quality of life. Although the primary manifestation of RA involves
the musculoskeletal system, it is increasingly recognized as a multi-organ disease with
diverse extra-articular complications.
Among the extra-articular manifestations, ocular involvement represents a significant
clinical concern due to its potential to impair vision and overall well-being. The eyes can be
affected through a variety of inflammatory processes, including keratoconjunctivitis sicca,
scleritis, and uveitis. These ocular complications may arise early or late in the course of RA
and can lead to serious consequences such as chronic pain, decreased visual acuity, or even
irreversible blindness if not identified and managed promptly.
Given the high prevalence of eye involvement in RA patients and its profound impact on
quality of life, timely diagnosis and appropriate treatment of ocular manifestations are
critical components of comprehensive patient care. The present study aims to explore the
types and clinical features of ocular involvement in rheumatoid arthritis, evaluate current
diagnostic approaches, and discuss effective management strategies. Understanding these
aspects will contribute to improved outcomes and better preservation of vision among RA
patients.
Rheumatoid Arthritis and the Involvement of the Eye in Its Pathogenesis
Rheumatoid arthritis (RA) is a chronic autoimmune disease primarily characterized by
persistent inflammation of the synovial joints. However, RA is a systemic condition,
meaning it can affect multiple organs and tissues beyond the joints, including the eyes. The
Vo
lu
m
e
5,
Ju
ne
,2
02
5
,
M
ED
IC
AL
SC
IE
N
CE
S.
IM
PA
CT
FA
CT
OR
:7
,8
9
involvement of the eye in RA is a result of complex autoimmune mechanisms and
inflammatory processes that contribute to ocular tissue damage and dysfunction.
Autoimmune Processes in the Eye
In RA, the immune system mistakenly targets the div's own tissues, leading to the
production of autoantibodies and immune complexes. These immune components can
circulate through the bloodstream and deposit in various organs, including ocular structures.
The eye’s tissues—such as the conjunctiva, sclera, uvea, and lacrimal glands—are
vulnerable to autoimmune attacks that trigger inflammation.
The formation of immune complexes and the activation of autoreactive T and B
lymphocytes result in an inflammatory cascade within the eye. This autoimmune response
disrupts normal tissue integrity and function, contributing to the development of ocular
manifestations such as dry eye syndrome, scleritis, and uveitis.
Inflammatory Mechanisms and Immunological Changes
Central to the pathogenesis of RA-associated ocular involvement is the dysregulation of
inflammatory mediators. Proinflammatory cytokines, including tumor necrosis factor-alpha
(TNF-α), interleukin-1 (IL-1), and interleukin-6 (IL-6), are produced in excess and
perpetuate inflammation within ocular tissues. These cytokines promote leukocyte
recruitment, vascular permeability, and tissue destruction.
Additionally, the disturbance in microcirculation caused by inflammation leads to increased
vascular permeability and edema, which further exacerbates tissue damage. The chronic
inflammatory environment alters the function of lacrimal glands, resulting in reduced tear
production and keratoconjunctivitis sicca (dry eye syndrome), one of the most common
ocular complications in RA.
Understanding these autoimmune and inflammatory processes is crucial for early detection
and targeted treatment of eye involvement in RA, aiming to prevent vision loss and improve
patients’ quality of life.
Clinical Manifestations of Ocular Involvement in Rheumatoid Arthritis
Rheumatoid arthritis (RA) is not only a disease affecting the joints but also one that
frequently involves the eyes, causing a range of ocular complications. These eye
manifestations can vary widely in their clinical presentation, severity, and potential to cause
vision impairment. The most common ocular conditions associated with RA include
keratoconjunctivitis sicca, scleritis, and uveitis.
Keratoconjunctivitis Sicca (Dry Eye Syndrome)
One of the most prevalent ocular complications in RA patients is keratoconjunctivitis sicca,
also known as dry eye syndrome. This condition arises due to inflammation and dysfunction
of the lacrimal glands, which are responsible for tear production. The resulting tear
deficiency leads to dryness, irritation, redness, and a burning sensation in the eyes. Patients
Vo
lu
m
e
5,
Ju
ne
,2
02
5
,
M
ED
IC
AL
SC
IE
N
CE
S.
IM
PA
CT
FA
CT
OR
:7
,8
9
often report discomfort, foreign div sensation, and sensitivity to light. If untreated,
keratoconjunctivitis sicca can cause corneal damage, including erosions and ulcerations,
potentially leading to decreased vision.
Scleritis and Episcleritis
Scleritis is a severe inflammation of the sclera, the white outer layer of the eyeball, which is
commonly seen in active RA. This condition is typically painful, with deep, boring eye pain
that may radiate to surrounding facial areas. It often causes redness and swelling and may
lead to complications such as scleral thinning and vision loss if not properly managed.
Episcleritis, a milder and more superficial inflammation of the episcleral tissue, can also
occur in RA patients, usually presenting with redness and mild discomfort but without
significant threat to vision.
Uveitis
Uveitis, inflammation of the uveal tract (including the iris, ciliary div, and choroid), can
present in RA either as anterior uveitis (iritis) or posterior uveitis. Patients with uveitis
experience eye pain, redness, photophobia, and blurred vision. Chronic or recurrent uveitis
may result in serious complications such as glaucoma, cataracts, or permanent vision loss.
Other Ocular Structural Changes
Beyond these primary inflammatory conditions, RA can affect other ocular structures.
Retinal vasculitis, optic neuritis, and changes in the eyelids and conjunctiva may occur.
These changes can contribute to visual disturbances and require careful ophthalmologic
assessment.
Visual Impairment and Its Complications
The ocular involvement in RA, if not promptly diagnosed and treated, can lead to
progressive visual impairment. Complications such as corneal damage, glaucoma, cataracts,
and optic nerve involvement pose significant risks to vision. Therefore, early recognition
and multidisciplinary management involving rheumatologists and ophthalmologists are
essential to preserving vision and improving patient outcomes.
Diagnostic Methods in Rheumatoid Arthritis-Associated Ocular Involvement
Accurate diagnosis of ocular complications in patients with rheumatoid arthritis (RA) is
crucial for timely intervention and prevention of vision loss. A combination of clinical
evaluation, specialized ophthalmologic techniques, and laboratory investigations are
employed to comprehensively assess the extent and nature of eye involvement.
Clinical Examination
The diagnostic process begins with a thorough clinical examination by the physician or
ophthalmologist. This includes detailed history-taking to document symptoms such as eye
pain, redness, dryness, photophobia, and visual changes. External inspection of the eyes
Vo
lu
m
e
5,
Ju
ne
,2
02
5
,
M
ED
IC
AL
SC
IE
N
CE
S.
IM
PA
CT
FA
CT
OR
:7
,8
9
assesses signs like conjunctival injection, eyelid abnormalities, swelling, and tear film
quality. Visual acuity testing is performed to evaluate any decline in vision. This initial
clinical assessment helps identify the need for further, more specialized diagnostic
procedures.
Ophthalmologic Techniques
1.
Slit-Lamp Examination:
This is a fundamental diagnostic tool that provides magnified
visualization of the anterior segment of the eye, including the cornea, conjunctiva, sclera,
iris, and anterior chamber. It allows detection of inflammatory signs such as keratitis,
conjunctivitis, scleritis, and anterior uveitis. The slit-lamp also helps evaluate tear film
stability and ocular surface integrity in dry eye syndrome.
2.
Optical Coherence Tomography (OCT):
OCT is a non-invasive imaging modality
that generates high-resolution cross-sectional images of the retina and other ocular structures.
It is particularly valuable for assessing retinal thickness, macular edema, and optic nerve
head changes, which may be affected in RA-related ocular disease.
3.
Fluorescein Angiography:
This diagnostic test involves the intravenous injection of
fluorescein dye followed by serial photography of the retinal vasculature. It helps detect
retinal vascular inflammation, leakage, ischemia, and neovascularization associated with RA
complications.
4.
Additional Imaging:
In some cases, ultrasound biomicroscopy or fundus photography
may be used to supplement diagnostic information.
Laboratory Investigations
Laboratory tests support the clinical and ophthalmological findings and help evaluate
systemic disease activity:
Rheumatoid Factor (RF) and Anti-Cyclic Citrullinated Peptide (Anti-CCP)
Antibodies:
These immunological markers assist in confirming RA diagnosis and
correlating disease severity.
Inflammatory Markers:
Elevated erythrocyte sedimentation rate (ESR) and C-reactive
protein (CRP) levels indicate systemic inflammation.
Cytokine Profiling:
Measuring serum levels of pro-inflammatory cytokines such as
tumor necrosis factor-alpha (TNF-α), interleukin-1 (IL-1), and interleukin-6 (IL-6) may
provide insight into disease activity and ocular inflammation.
Together, these diagnostic approaches enable a comprehensive evaluation of ocular
involvement in RA, guiding effective treatment strategies and improving patient outcomes.
Treatment Approaches for Ocular Involvement in Rheumatoid Arthritis
Management of ocular complications in rheumatoid arthritis (RA) requires an integrated
approach involving both rheumatologic and ophthalmologic care to effectively control
systemic inflammation and prevent vision loss.
Rheumatologic and Ophthalmologic Strategies
Vo
lu
m
e
5,
Ju
ne
,2
02
5
,
M
ED
IC
AL
SC
IE
N
CE
S.
IM
PA
CT
FA
CT
OR
:7
,8
9
Effective treatment begins with close collaboration between rheumatologists and
ophthalmologists. Rheumatologists focus on controlling systemic autoimmune activity using
disease-modifying antirheumatic drugs (DMARDs), while ophthalmologists manage
localized eye inflammation and complications. Regular monitoring and interdisciplinary
communication ensure that treatment is tailored to the patient’s overall disease status and
ocular findings.
Pharmacological Treatments
1.
Corticosteroids:
These are cornerstone agents for rapidly reducing inflammation.
Topical corticosteroids (eye drops) are commonly used for anterior segment inflammation
such as keratitis, conjunctivitis, and anterior uveitis. In more severe cases, periocular or
systemic corticosteroids may be necessary to control deeper ocular inflammation like
posterior uveitis or scleritis. However, prolonged use requires careful monitoring due to
potential side effects like increased intraocular pressure and cataract formation.
2.
Immunosuppressive Agents:
For long-term disease control and steroid-sparing effect,
immunosuppressants are employed. Common drugs include methotrexate, azathioprine, and
cyclosporine, which reduce autoimmune activity both systemically and in the eye. These
agents help prevent recurrent inflammation and progression of ocular damage.
3.
Biologic Therapies:
Recent advances have introduced biologics targeting specific
inflammatory cytokines such as tumor necrosis factor-alpha (TNF-α) inhibitors (e.g.,
etanercept, infliximab) and interleukin blockers. These agents have shown efficacy in
controlling both joint and ocular inflammation in refractory RA cases and improving patient
outcomes.
Current and Emerging Treatment Modalities
Ongoing research aims to refine therapeutic strategies, minimize side effects, and improve
quality of life. Novel targeted therapies, including small molecule inhibitors and Janus
kinase (JAK) inhibitors, are being explored for their potential benefits in RA-associated
ocular disease. Additionally, advancements in drug delivery systems such as sustained-
release implants and nanotechnology may enhance local treatment efficacy while reducing
systemic exposure.
Overall, an individualized treatment plan combining systemic immunomodulation and local
ocular therapy is essential. Early diagnosis and timely intervention remain critical to
preserving vision and preventing irreversible ocular complications in rheumatoid arthritis
patients.
Analysis and Discussion
Prevention and Management of Ocular Involvement in Rheumatoid Arthritis
Preventing ocular complications in rheumatoid arthritis (RA) requires early detection and
comprehensive management of systemic inflammation. Regular ophthalmologic
examinations play a crucial role in identifying early signs of eye involvement, allowing
timely therapeutic interventions that can prevent progression to severe vision impairment.
Patient education on recognizing ocular symptoms and adherence to treatment regimens also
Vo
lu
m
e
5,
Ju
ne
,2
02
5
,
M
ED
IC
AL
SC
IE
N
CE
S.
IM
PA
CT
FA
CT
OR
:7
,8
9
contribute significantly to better outcomes. Immunomodulatory therapy aimed at controlling
systemic disease activity is fundamental in minimizing ocular damage.
Challenges in Clinical Practice
Despite advances in diagnostics and treatment, managing RA-related ocular manifestations
poses several challenges. The heterogeneous presentation of eye involvement often
complicates early diagnosis, particularly in asymptomatic patients or those with mild
symptoms. Additionally, balancing systemic immunosuppression to control RA while
minimizing adverse effects remains complex, especially in patients with comorbidities.
Access to specialized multidisciplinary care may be limited in some regions, impacting
comprehensive management. Finally, long-term follow-up is essential but can be hindered
by patient compliance issues and healthcare resource constraints.
Practical Significance of the Research Findings
This study highlights the importance of integrating rheumatologic and ophthalmologic
approaches for optimal care of RA patients. Understanding the underlying
immunopathogenesis and clinical spectrum of ocular involvement informs better diagnostic
and therapeutic strategies. Early recognition and intervention not only preserve vision but
also improve overall quality of life. The findings support the need for standardized screening
protocols and increased awareness among healthcare providers and patients.
Conclusion
Key Findings and Recommendations
Rheumatoid arthritis is a systemic autoimmune disease with significant ocular morbidity that
can severely impact patients’ quality of life. The eye involvement ranges from mild surface
inflammation to sight-threatening conditions such as uveitis and optic neuritis. Early
diagnosis through regular clinical and specialized ophthalmologic assessments is vital for
effective management.
Treatment requires a multidisciplinary approach combining systemic immunosuppressive
therapy and local ocular treatments. Corticosteroids and immunomodulatory drugs remain
the mainstay of therapy, while emerging biologic agents offer promising results in refractory
cases.
To optimize outcomes, it is recommended to:
Implement routine ophthalmologic screening for all RA patients.
Educate patients on early symptoms of ocular involvement.
Foster collaboration between rheumatologists and ophthalmologists.
Explore and adopt novel therapeutic agents and delivery systems.
Ensure long-term follow-up to monitor disease progression and treatment response.
By adhering to these principles, healthcare providers can reduce ocular complications and
improve the visual and overall health outcomes of patients with rheumatoid arthritis.
Vo
lu
m
e
5,
Ju
ne
,2
02
5
,
M
ED
IC
AL
SC
IE
N
CE
S.
IM
PA
CT
FA
CT
OR
:7
,8
9
References
9. McGonagle D, Tan AL, Benjamin M. The role of the synovium in rheumatoid arthritis.
J Clin Rheumatol. 2017;23(2):72-81.
10. Sivaraj RR, Smith JA. Ocular manifestations of rheumatoid arthritis: beyond
keratoconjunctivitis sicca. Curr Opin Rheumatol. 2010;22(1):95-101.
11. Zakka LR, Fraunfelder FW, Rosenbaum JT. Rheumatoid arthritis-associated uveitis.
Curr Opin Rheumatol. 2015;27(5):456-462.
12. Foster CS, Vitale AT. Diagnosis and Treatment of Uveitis. 2nd ed. Saunders Elsevier;
2002.
13. Wolfe F, Michaud K. The clinical and radiographic course of rheumatoid arthritis over
10 years. J Rheumatol. 2011;38(3):459-468.
14. Zhang J, Yang J, Xie J. Advances in understanding the ocular pathogenesis in
rheumatoid arthritis. Autoimmun Rev. 2020;19(10):102569.
15. McGonagle D, Aydin SZ, Gualtierotti R. Autoimmune aspects of scleritis. Nat Rev
Rheumatol. 2017;13(12):719-729.
16. Ohno S, Nanke Y. New insights into ocular complications in rheumatoid arthritis:
Immunopathology and management. J Immunol Res. 2019;2019:2454713.
